Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Nov;21(11):2305-10.
doi: 10.1007/s00330-011-2200-9. Epub 2011 Jul 16.

Late adverse reactions to intravascular iodine based contrast media: an update

Collaborators, Affiliations

Late adverse reactions to intravascular iodine based contrast media: an update

Marie-France Bellin et al. Eur Radiol. 2011 Nov.

Abstract

Definition: Late adverse reactions (LAR) to contrast media (CM) are defined as reactions occurring 1 h to 1 week after exposure.

Need for review: In view of more prospective studies of LAR and new data about their pathophysiology, the Contrast Medium Safety Committee (CMSC) of the European Society of Urogenital Radiology (ESUR) reviewed the literature on LAR and updated their guidelines.

Clinical features and pathology: LAR after CM include symptoms such as nausea, vomiting, headache, itching, skin rash, musculoskeletal pain, and fever. Skin reactions are well-documented LAR to CM with an incidence of approximately 2%-4% after nonionic monomers. LAR are commoner by a factor of three to four after nonionic dimers. The commonest skin reactions are maculopapular rashes, erythema and skin swelling. These reactions are T cell-mediated immune reactions, and the diagnosis may be confirmed using skin tests (patch or delayed reading intradermal). The main risk factors for LAR are a previous reaction to contrast medium, a history of allergy, and interleukin-2 treatment. Most skin reactions are mild or moderate and self-limiting.

Management: Management is symptomatic and similar to the management of other drug-induced skin reactions. To reduce the risk of repeat reactions avoidance of the relevant CM and any cross-reacting agents identified by skin testing is recommended.

PubMed Disclaimer

References

    1. Eur Radiol. 2003 Jan;13(1):185-94 - PubMed
    1. J Allergy Clin Immunol. 2005 Jan;115(1):179-85 - PubMed
    1. JAMA. 1986 Dec 26;256(24):3358-63 - PubMed
    1. Emerg Radiol. 2006 Jul;12(5):210-5 - PubMed
    1. Br J Radiol. 1986 Jun;59(702):620-1 - PubMed

LinkOut - more resources